Tryptamine TherapeuticsEXOPF
13F holders, Q3 2025 (September 30)1holders
0new positions
0sold out
$0.03avg. 13F price*
At the end of Q3 2025, 1 institutions reported holding Tryptamine Therapeutics Ltd. (EXOPF) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holder was Financially Speaking Inc ($10K).
- Company
- Tryptamine Therapeutics Ltd.
- CUSIP
- Q9240A100
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Financially Speaking Inc | 0.01% | No change | 361,600 | $10K |
"% of holder's portfolio" is EXOPF's weight in each manager's 13F, not the share of Tryptamine Therapeutics Ltd. the manager owns.